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Pneumocystis pneumonia (PCP) caused by the oppor-
tunistic fungal agent Pneumocystis jirovecii (formerly
P. carinii) continues to cause illness and death in HIV-
infected patients. In the absence of a culture system to iso-
late and maintain live organisms, efforts to type and
characterize the organism have relied on polymerase chain
reaction–based approaches. Studies using these methods
have improved understanding of PCP epidemiology, shed-
ding light on sources of infection, transmission patterns,
and potential emergence of antimicrobial resistance. One
concern, however, is the lack of guidance regarding the
appropriateness of different methods and standardization
of these methods, which would facilitate comparing results
reported by different laboratories.
Pneumocystis pneumonia (PCP) has been known formany years to be a disease of immunocompromised
persons. Before the AIDS epidemic, it had been reported as
a cause of death in malnourished infants (1). No standard-
ized in vitro propagation system is currently available;
consequently, much of the basic biology and epidemiology
of Pneumocystis spp. remains poorly understood.
Advances made over the last 15 years have been largely
due to the use of molecular biologic approaches.
For almost 80 years, Pneumocystis jirovecii (formerly
carinii) was considered to be a protozoan. In 1988, DNA
studies clearly demonstrated that it was not a single species
but a complex group of eukaryotic microorganisms, which
were assigned to the kingdom Fungi (2–4) at the branch
point between Ascomycota and Basidiomycota (5). 
Many genetic typing methods use DNA sequencing
approaches, but others use specific gene probes, single-
strand conformation polymorphism (SSCP), or restriction
fragment length polymorphisms (RFLP). Genetic typing
has shown Pneumocystis biodiversity (6), environmental
reservoirs (7,8), person-to-person transmission (9,10),
recurrent infections (11), subclinical colonization and car-
riage (12–14), clinical manifestations (15), and sulfa expo-
sure and suspected treatment or prophylaxis failures
(16–19). These studies changed our epidemiologic under-
standing of PCP, and more studies now suggest collective-
ly that a number of clinical PCP cases are newly acquired
rather than activated latent infections (9–12,18). 
In laboratories around the world, a number of typing
procedures, each with its own strengths and weaknesses,
are in use to address the clinical and epidemiologic issues
discussed above. In the following sections, we discuss the
most common methods, along with examples of how they
have been used in molecular epidemiologic studies of PCP. 
Different Typing Methods
A variety of typing methods have been used for
Pneumocystis genetic analysis, and a large number of
gene loci have been examined. We focus on the methods
and genes that have been most widely used for molecular
epidemiologic analyses or have the greatest potential
application. 
DNA Sequence Analysis
Direct DNA sequence analysis is the most common
approach currently used for Pneumocystis biodiversity and
molecular typing studies. Sequence analysis of the
thymidylate synthase (TS) and superoxide dismutase
(SODA) gene loci, the EPSP synthase domain of the multi-
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functional arom gene, and the mitochondrial small subunit
ribosomal RNA (mt SSU rRNA) locus have been used to
distinguish Pneumocystis species from diverse mammalian
hosts (6,20,21). Because of the generally low sequence
divergence among P. jirovecii isolates at these loci, they are
not highly discriminative for P. jirovecii typing. Several
additional loci, however, have proved useful for molecular
epidemiologic applications (7–19). These include the inter-
nal transcribed spacer (ITS) regions of the nuclear rRNA
operon (9,10,15), the mitochondrial large subunit riboso-
mal RNA locus (mt LSU rRNA) (7,8,10), and the dihy-
dropteroate synthase (DHPS) gene (10,16–19).
ITS1 and ITS2
The ITS1 sequence is located on the nuclear rRNA
operon between the genes of the 18S rRNA and the 5.8S
rRNA, and ITS2 is located between the genes of the 5.8S
rRNA and the 26S rRNA (22). These noncoding loci are
spliced during rRNA synthesis. They show a high level of
polymorphism, which has been used for genetic typing
applications. The first ITS typing system was developed
by Lu et al. (22). Using their nomenclature, in which ITS1
alleles are designated with an uppercase letter and ITS2
alleles with a lowercase letter, 15 ITS1 alleles (from A to
O) and 14 ITS2 alleles (from a to n) have been described.
Based of this amount of DNA polymorphism, a total of
210 P. jirovecii types are theoretically possible, with 59
types reported by these authors (22,23). 
A second ITS typing scheme was developed by Tsolaki
et al. (24–26) and is based on nucleotide variation at four
positions in the ITS1 and at six positions in the ITS2.
According to their nomenclature scheme, ITS1 alleles are
designated by using an uppercase letter associated with a
numerical subscript, and ITS2 alleles are designated by
using a lowercase letter also associated with a numerical
subscript. These researchers described six ITS1 alleles and
nine ITS2 alleles; these numbers allow for up to 54 poten-
tial P. jirovecii ITS types, should all possible combinations
exist. Laboratories currently using this typing scheme have
reported ≈40 different P. jirovecii ITS types. The most fre-
quent types are B1a3 and B2a1, which have both been iden-
tified in one third of all P. jirovecii isolates typed to date.
More recently, Nimri et al. (27) added to the count of
Lee et al. by identifying 12 previously unreported ITS1
alleles and 16 previously unreported ITS2 alleles. In the
study by Nimri et al., 36 ITS types were noted in 180
sequences examined from 60 samples. Although the typing
methods of Lee et al. and Tsolaki et al. are not strictly iden-
tical, a general correspondence between P. jirovecii ITS
types can be observed with either method. To date, approx-
imately 87 unique ITS types have been identified by the
two methods. 
mt LSU rRNA
The amount of polymorphism reported at this locus is
substantially less than that reported for ITS; nevertheless,
the variation observed has helped address a number of
important epidemiologic questions. The original PCR
assay developed for this locus was a single-round PCR that
generated a fragment of ≈360 bp (28). A nested PCR assay
has also been developed (25), which has an increased sen-
sitivity and specificity. Recently, this test was used to dis-
tinguish subclinical carriage from clinical disease (14). 
Polymorphism at this locus is routinely reported at two
nucleotide positions (85 and 248), showing six unique
genotypes. A third variable position has been reported but
is rarely seen. Mitochondrial DNA has long been accepted
and used as a practical and reproducible tool to evaluate
intraspecific variation. Since multiple mitochondria are
present in individual organisms but display the same hap-
lotype, mitochondrial loci are more easily detected by PCR
than single-copy nuclear genes, which results in generally
higher PCR sensitivities. 
The DHPS Locus
The DHPS locus encodes the key enzyme that is target-
ed by sulfonamide antimicrobial drugs. Consequently, typ-
ing efforts involving this gene have been directed
primarily at demonstrating an association between treat-
ment or prophylaxis failures and the specific mutations
observed at this locus (16–19). Polymorphism at this locus
has been observed primarily at amino acid positions 55 and
57, where nonsilent mutations have been shown to corre-
late with sulfonamide exposure and prophylaxis and treat-
ment failure. A nested-PCR assay has been developed for
this locus (29), with modifications suggested by other
investigators (18). This assay is highly sensitive and spe-
cific for P. jirovecii in patients with clinical PCP. In addi-
tion to the position 55/57 mutations, nucleotide
polymorphism has also been observed at several other sites
in the gene (30). These mutations have not been shown to
result in amino acid substitutions and have not been corre-
lated with adverse clinical outcomes.
Multitarget PCR-SSCP
A second method for molecular typing P. jirovecii
involves single-strand confirmation polymorphism (SSCP)
analysis (31,32). The method consists of PCR amplification
of four variable regions of P. jirovecii (Table), then detect-
ing polymorphism by observing migration pattern variation
in gel electrophoresis. The variable regions analyzed
include ITS1, the intron of the nuclear 26S rRNA gene
(26S), the variable region of the mt LSU rRNA, and the
region surrounding an intron of the β-tubulin gene (β-tub). 
A variable region amplified from a clinical specimen of
a given patient with PCP can generate a simple or complex
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SSCP pattern. Simple patterns are made of two bands and
correspond to a single allele of the genomic region.
Complex patterns are made of more than two bands and
have been shown to correspond to the superimposition of
two simple patterns and the presence of two or, rarely,
three alleles of the region (32). 
According to their SSCP results, different categories of
specimens can be distinguished (32). A specimen harbor-
ing a single allele at each of the four genomic regions is
presumably infected with a single P. jirovecii type, and
each combination of four simple SSCP patterns defines a
type (Figure 1). Studies strongly suggest that a patient har-
boring two or more alleles of at least one of the genomic
regions is coinfected with several P. jirovecii types (31).
Analysis of the alleles and their abundance within the com-
plex patterns allows identification of the coinfecting types
in ≈60% of specimens coinfected with two types.
Specimens producing at least one complex SSCP pattern
made of three simple patterns are presumably infected with
at least three types, which cannot be identified. However,
the SSCP results of the latter specimens are also informa-
tive, as they often allow exclusion of certain specific types.
Among 430 specimens from 15 hospitals in five European
countries, three to five different simple SSCP patterns
could be identified for each genomic region and 43 differ-
ent P. jirovecii types. Thirty percent of the patients were
infected with a single P. jirovecii, 45% with two types, and
25% with three (31,32). 
Major Surface Glycoprotein Expression Site Typing
A third, recently reported typing method relies on iden-
tifying the number of tandem repeats in the intron of the
expression site of the major surface glycoprotein (MSG) of
P. jirovecii (Table) (33). Unlike the other currently avail-
able typing methods, which rely on identifying single
nucleotide polymorphisms or combinations of such poly-
morphisms, this method relies on characterizing the size of
a region of this intron. Within this region, different P.
jirovecii isolates have two to six copies of a 10-nt
sequence. Typing can be performed by amplifying this
region with PCR using primers flanking this region and
running the PCR product on a high-resolution acrylamide
gel that can separate fragments that differ in size by a few
base pairs (33). 
PCR followed by electrophoresis can be used to rapid-
ly determine the number of repeats present in the intron.
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Because the expression site of the MSG (unlike the MSG
itself) is present as a single copy per organism (34,35), a
given strain of P. jirovecii will have a unique number of
repeats per organism. Infections with more than one strain
of P. jirovecii, which occur frequently in HIV-infected
patients (20%–70% of patients) can be easily detected with
this method if the different strains have a different number
of repeats, since PCR amplification will result in multiple
bands corresponding to the different sizes of the repeats
(Figure 2).
The utility of this typing method can be enhanced by
sequencing the amplified PCR product because the 10-bp
repeats can have one of three sequences (types 1, 2, and 3),
which differ from each other by a single nucleotide.
Isolates with the same number of repeats can potentially be
distinguished from each other by different patterns of
repeat types (e.g., three repeats of type 1, 1, 2 are different
from three repeats of type 1, 2, 2). However, in isolates
with multiple strains of P. jirovecii, as determined by quan-
tifying the number of repeats, directly sequencing the PCR
product will sequence only the predominant strain.
Because adding or deleting 10 bases will shift the homol-
ogous sequences by 10, bases will be out of alignment
downstream of the shift, making sequencing difficult.
Subcloning, followed by sequencing, must be used in these
circumstances to determine sequences of minority strains.
Analyzing the sequence of repeats also may provide
insight into the evolution of P. jirovecii. The single base-
pair changes seen in repeats likely occurred on a single
occasion: since such a mutation appears to be rare (only
two unique mutations have been identified) and likely does
not confer a biologic advantage to the organism, the same
mutation would not likely occur in the same location at dif-
ferent times. Thus, organisms with the 1, 1, 2 pattern of
three repeats must have derived from a parental strain with
a 1, 2 pattern of two repeats, rather than a 1, 1 pattern of
two repeats, both of which have been seen in separate iso-
lates (Figure 3). An analysis of multiple isolates from
around the world will potentially provide information
about the evolution and spread of P. jirovecii. If archival
isolates can be identified and examined, we may gain addi-
tional information about the evolution of the organism
over time. 
Because this method was only recently described, it has
been used by one group to date. In these limited studies of
147 samples from the United States and Europe, three
repeats were most commonly seen, either alone or in com-
bination (33). Two and four repeats were seen less fre-
quently, five repeats were seen only in two mixed
infections, and six repeats were seen in two isolates, one of
which was in a mixed infection with three and four repeats.
No pattern related to time of obtaining the sample
(1974–2001) or geographic location was identified.
Coinfection with more than one strain was identified in
43% of the 147 samples with this method. Additional
experience with this typing method, alone and in combina-
tion with other methods, is needed to better evaluate its
utility in understanding the importance of strain variation
and in studying the epidemiology and biologic variability
of this organism. 
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Figure 1. Schematic representation of the
single-strand conformation polymorphism
(SSCP) patterns of four variable regions
used to type Pneumocystis jirovecii. Each
lane corresponds to a hypothetical sam-
ple. All simple patterns with two bands for
each region are shown. Each uppercase
letter represents a simple SSCP pattern.
For each region, the complex SSCP pat-
tern A,B corresponding to the superimpo-
sition of simple patterns A and B is
represented. The complex ITS1 pattern
A,B, is demonstrated, in which pattern A is
more abundant than pattern B. Reprinted
with permission from reference 32.
Hauser et al. 2001, AIDS:15(4):461–466.
Figure 2. Representative denaturing gel elec-
trophoresis analysis of Pneumocystis jirovecii tan-
dem repeats in clinical isolates. Numbers above
each lane represent individual isolates. Lane M is a
mixture of polymerase chain reaction products from
five isolates, of which the number of repeats was 2,
3, 4, 5, and 6 (shown above DNA bands), as deter-
mined by sequencing. Reprinted from (33) with per-
mission from the University of Chicago Press.
Assay Stability and Reproducibility 
A potential limitation in typing that should be consid-
ered in evaluating the various approaches is the shortage of
information available on marker stability and assay stabil-
ity. While these data are generally lacking for most of the
commonly used approaches, efforts have been made to
evaluate and validate stability over time of multitarget
PCR-SSCP (32). Specifically, pairs of specimens collected
from the same patients during a single PCP episode were
analyzed to evaluate the stability of genetic markers.
Markers remained stable throughout the 8-week study,
which suggests that this method was valid for most clini-
cal applications. Less formal evaluations with direct DNA
sequencing show a similar level of stability with the con-
served gene loci mt LSU rRNA and DHPS (C.B. Beard,
unpub. data). Unexpectedly high rates of ITS variability
have been reported in samples collected from the same
patient at different times during a single disease episode
(36). Several possible explanations were proposed, includ-
ing quantitative changes in the relative abundance of
mixed P. jirovecii populations, sampling bias, intrinsic
instability of the gene locus, and methodologic artifact.
Others have observed similar variation patterns at this
locus (C.B. Beard, unpub. data), and the explanation is a
subject of debate. 
Typing-related Analyses 
Two other molecular approaches may address clinical
or epidemiologic questions. These applications differ from
most typing efforts in that the usual purpose of typing is to
evaluate genetic polymorphism, whereas these assays
examine organism numbers and viability. A recently devel-
oped quantitative PCR assay based on a conserved region
of the MSG gene provides a sensitive method for quantify-
ing organism load in oral washes of patients with suspect-
ed PCP (37,38). In the absence of a reliable culture system,
PCR-based viability assays directed against mRNA targets
have been also been developed (39,40). Since these appli-
cations go beyond the scope of this article, they will not be
discussed further; however, they are useful for clinical and
molecular epidemiologic studies. 
Best Typing Method
Much consideration has been given to the question of
the best genes and best approaches for molecular typing.
The answer in most cases will be determined by the typing
objective. One consideration is the evolutionary rate of the
gene. In most eukaryotic organisms, mitochondrial DNA
has been reliable for examining intraspecific variation. In
P. jirovecii, the mt LSU rRNA locus has generated useful
data for addressing specific epidemiologic questions
(7,8,10). A greater level of intraspecific variation (22–27),
however, can be detected by using the ITS locus because
of its more rapid evolution. Two potential complications
associated with the ITS locus are related to assay stability:
the specific gene sequence, which includes a polynu-
cleotide stretch of ≈9–12 thymidines that can lead to Taq
polymerase error during amplification, and the possibility
that multiple genotypes occurring in a single isolate could
result from two indistinguishable sources, coinfecting P.
jirovecii strains, or diploid heterozygote organisms in the
sample. These concerns do not imply that the locus should
not be used but only that these possibilities should be con-
sidered when interpreting the data. 
The mt LSU rRNA and ITS loci are frequently used
because they are not assumed to be under genetic selection
and are therefore useful for elucidating molecular evolu-
tionary phenomena that provide the basis for understand-
ing the history of circulating strains. Sometimes, however,
typing is employed specifically to determine the existence
of genetic selection, such as that induced by exposure to
antimicrobial agents (16–19). Care must be taken in draw-
ing inferences from differences observed at loci that are
under genetic selection, since selection can confound
inferences concerning strain differences. 
DNA sequencing provides the most exhaustive amount
of information about any particular DNA fragment, but it
is expensive and labor-intensive. Fragment analysis
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Figure 3. A model for the evolution of tandem repeats in
Pneumocystis jirovecii, for repeat patterns that have been identi-
fied to date. The number of repeats is indicated on the left. The
specific pattern of repeats is indicated on the right. The numbers
1, 2, and 3 represent three different repeat types with sequence
variation in the first and fourth nucleotides. The repeat patterns
that were not identified in this study but are postulated to exist, on
the basis of identified patterns, are boxed. Solid arrows indicate
potential evolution between isolates that have been identified, and
dashed arrows indicate evolution between postulated isolates.
Reprinted from (33) with permission from the University of Chicago
Press.
methods such as SSCP are simpler and less expensive, but
they rely on having sequence data to characterize the pat-
terns observed. SSCP is also limited in its ability to inter-
pret new genotypes. Both multilocus DNA sequencing and
multitarget PCR-SSCP can incorporate information from
multiple genetic loci, which allows higher discriminating
power to identify strain differences. Low-resolution meth-
ods (e.g., RFLP) are best used when the goal is to look
only for specific RFLP-defined mutations. Either SSCP or
DNA sequencing is suitable for most molecular epidemio-
logic studies. 
Need To Standardize Reporting
The greatest need in standardization is adopting well-
defined sequence types. A good example is the convention
used with discussing DHPS mutations, in which the
nucleotide or amino acid position is given, along with the
specific identity (e.g., Thr > Ala at position 55 and Pro >
Ser at position 57 to denote the DHPS double mutant geno-
type). Using arbitrarily defined numbers or other alphanu-
meric characters to define genotypes should be avoided,
except perhaps for brevity in an article in which observed
genotypes are all defined by nucleotide position and iden-
tity in a table. The nomenclature systems developed for the
ITS locus should be reevaluated; authors’ intentions were
good, but they did not account for the variation possible at
that locus. A better nomenclature scheme would be to use
the specific nucleotide position or variant relative to the
original GenBank consensus sequence for that locus, as is
typically done when reporting mutations. With the
Pneumocystis genome project under way and as more
genes are cataloged, nomenclature will need to be stan-
dardized further, such as with three-letter designations for
genes. Within the Pneumocystis field, current practice is to
use four or more letters to define some loci (e.g., DHFR,
DHPS, MTLSU rRNA). Nomenclature standardization,
however, should not affect the adoption of standardized
typing methods using selected gene targets for specific
molecular epidemiologic applications. 
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